ADHD drugs and cardiovascular risk [19]

New England Journal of Medicine

Volumn 354, Issue 21, 2006, Pages 2296-

  Anders, Thomas ^a   Sharfstein, Steven ^b  

^a American Academy of Child and Adolescent Psychiatry   (United States)

^b AMERICAN PSYCHIATRIC ASSOCIATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT;

ATTENTION DEFICIT DISORDER; CARDIOVASCULAR RISK; HUMAN; LETTER; PRIORITY JOURNAL; PSYCHOTHERAPY;

EID: 33646860996     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc061187     Document Type: Letter

References (5)

1. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006;354:1445-8.
2. Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child 2005;90:Suppl 1:i2-i7.
3. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder: Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999;56:1073-86.
4. Greenhill LL, Kollins S, Abikoff H, et al. Efficacy of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry (in press).
5. Wigal T, Greenhill LL, Chuang S, et al. Tolerability and safety of methylphenidate in preschooler children with ADHD. J Am Acad Child Adolesc Psychiatry (in press).